New Hepatitis B Drug Cures 1 in 5 Patients in Trials

An experimental treatment by GSK achieved functional cures for nearly 20% of hepatitis B patients in major clinical trials, a massive leap from the 1-3% success rate of current medications.

The breakthrough offers hope for millions living with a virus that kills a million people annually.